CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH Blinatumomab Enhances Treatment Outcomes in MRD-Negative ALL, Potentially Impacting Long-Term Prognosis
A recent phase 3 trial evaluated the efficacy of adding blinatumomab to consolidation chemotherapy in adults with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) who achieved measurable residual disease (MRD)-negative remission. The study demonstrates significant improvements in overall survival and relapse-free survival with the addition of blinatumomab.
Study Design:
- Randomized phase 3 trial
- Patients: 30-70 years old with BCR::ABL1-negative BCP-ALL
- MRD-negative remission (<0.01% leukemic cells in bone marrow)
- 224 patients randomized to two groups of 112 each
- Intervention: Four cycles of blinatumomab + four cycles of consolidation chemotherapy vs. four cycles of consolidation chemotherapy alone
- Primary endpoint: Overall survival
- Secondary endpoint: Relapse-free survival
- Median follow-up: 43 months
Key Findings:
- Overall survival at 3 years: 85% (blinatumomab group) vs. 68% (chemotherapy-only group)
- Hazard ratio for death: 0.41 (95% CI, 0.23 to 0.73; P=0.002)
- 3-year relapse-free survival: 80% (blinatumomab) vs. 64% (chemotherapy alone)
- Hazard ratio for relapse or death: 0.53 (95% CI, 0.32 to 0.87)
- Higher incidence of neuropsychiatric events in the blinatumomab group
HCN Medical Memo
The addition of blinatumomab to consolidation chemotherapy represents a promising advancement in the treatment of MRD-negative BCP-ALL in adults. Although the improved survival outcomes are encouraging, clinicians should be aware of the potential for increased neuropsychiatric events. Careful patient selection and monitoring may be necessary to optimize the risk-benefit profile of this treatment approach.
More on Leukemia
